Status:
COMPLETED
A Study of the Effect of Taspoglutide on Gastric Emptying in Patients With Type 2 Diabetes
Lead Sponsor:
Hoffmann-La Roche
Conditions:
Diabetes Mellitus Type 2
Eligibility:
All Genders
18-75 years
Phase:
PHASE3
Brief Summary
This 3 arm, placebo-controlled study will investigate the effect of Taspoglutide on gastric emptying in patients with type 2 diabetes. Patients will be randomized into one of 3 groups to receive a)10m...
Eligibility Criteria
Inclusion
- adult patients, 18-75 years of age;
- type 2 diabetes mellitus, treated with stable oral antidiabetic drug therapy for \>=3 months prior to screening;
- stable weight +/-10% for \>=3 months before screening.
Exclusion
- type 1 diabetes mellitus;
- acute gastrointestinal symptoms at screening and/or day -1;
- clinically relevant cardiovascular, bronchopulmonary, gastrointestinal or neurological disease.
Key Trial Info
Start Date :
December 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2009
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT00809705
Start Date
December 1 2008
End Date
October 1 2009
Last Update
November 2 2016
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Berlin, Germany, 14050
2
Neuss, Germany, 41460
3
London, United Kingdom, HA1 3UJ